ArticleJournal of food and drug analysis2025

Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway.

Man-Chen Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.